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Abstract
Background: Heart failure remains a major cause of mortality in thalassaemia major. The possible role of cardiac
fibrosis in thalassemia major in the genesis of heart failure is not clear. It is also unclear whether cardiac fibrosis
might arise as a result of heart failure.
Methods: We studied 45 patients with thalassaemia major who had a wide range of current cardiac iron loading
and included patients with prior and current heart failure. Myocardial iron was measured using T2* cardiovascular
magnetic resonance (CMR), and following this, late gadolinium enhancement (LGE) was used to determine the
presence of macroscopic myocardial fibrosis.
Results: The median myocardial T2* in all patients was 22.6 ms (range 5.3-58.8 ms). Fibrosis was detected in only
one patient, whose myocardial T2* was 20.1 ms and left ventricular ejection fraction 57%. No fibrosis was identified
in 5 patients with a history of heart failure with full recovery, in 3 patients with current left ventricular dysfunction
undergoing treatment, or in 18 patients with myocardial iron loading with cardiacT2* < 20 ms at the time of scan.
Conclusion: This study shows that macroscopic myocardial fibrosis is uncommon in thalassemia major across a
broad spectrum of myocardial iron loading. Importantly, there was no macroscopic fibrosis in patients with current
or prior heart failure, or in patients with myocardial iron loading without heart failure. Therefore if myocardial
fibrosis indeed contributes to myocardial dysfunction in thalassemia, our data combined with the knowledge that
the myocardial dysfunction of iron overload can be reversed, indicates that any such fibrosis would need to be
both microscopic and reversible.
Introduction
Thalassaemia is the commonest single gene disorder
worldwide, with approximately 94 million heterozygotes
for beta thalassaemia and 60,000 homozygotes born
each year [1]. Life-long blood transfusions are required
for survival in thalassemia major, but with each unit of
blood carrying 200-250 mg of iron, the transfusions
result in tissue iron loading and multiple organ compli-
cations. Myocardial siderosis is the major cause of mor-
tality and is dominantly manifested as heart failure [2],
which typically has a disguised onset that may deterio-
rate catastrophically as a result of a vicious cycle of
increasing intracellular iron levels. This toxic cardio-
myopathy can be reversible if chelation is commenced
early [3], although it may take years to reduce cardiac
storage iron levels to normal. Although heart failure is
clearly related to intracardiac iron, it is less clear
whether there is an additional contribution from myo-
cardial fibrosis. Myocardial fibrosis could reduce both
systolic function and ventricular compliance which
could aggravate iron mediated cardiac dysfunction.
Another possibility is that cardiac fibrosis might occur
as a result of periods of cardiac failure, and therefore its
occurrence might indicate previous cardiac damage with
recovery. Historical papers have suggested that cardiac
fibrosis is a major pathological component of heart fail-
ure and death in cardiac siderosis [4-6], but this data is
up to 50 years old and may be misleading in the current
era of iron chelation treatment. There is rather little
contemporary data examining the histological incidence
of fibrosis in cardiac iron overload [7-9], and its relation
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to ventricular function and iron levels in thalassaemia
patients [10].
Cardiac fibrosis can be studied using late gadolinium
enhancement (LGE) cardiovascular magnetic resonance
(CMR). This technique uses an injection of a gadolinium
chelate which is an MR contrast agent that concentrates
in areas of expanded extracellular space, such as myocar-
dial fibrosis, from 10 minutes after injection. LGE has
been widely used to examine the role of replacement
macroscopic fibrosis in a range of cardiomyopathies
[11-14], and the occurrence of LGE is associated with the
development of cardiac events, such as heart failure and
arrhythmias [15-17]. CMR has also been used widely to
measure storage cardiac iron with the T2* technique [18],
which is non-invasive, reproducible [19,20], calibrated to
cardiac iron levels [21-23], and a valuable technique to
assess the efficacy of cardiac iron chelators [3,24-26]. We
therefore used LGE and cardiac T2* to investigate the inci-
dence of fibrosis and its correlation with myocardial iron
and myocardial function in thalassaemia major patients.
Methods
Patients
A total of 45 patients with beta-thalassaemia major were
included in this study. Patients were referred for clinical
evaluation according to local practice at external refer-
ring centers. There were 19 male and 26 female patients
with a mean (±SD) age of 27.1 ± 9.6 years. This research
had full ethical approval through Trent NHS Ethics
Committee, and all patients gave written consent.
Cardiovascular Magnetic Resonance
Patients were scanned at 1.5 T (Sonata, Siemens Medi-
cal Solutions, Erlangen, Germany) using previously
reported techniques [18]. In brief, T2* CMR was per-
formed using a cardiac gated, single breath-hold, 8-echo
sequence (2.6 - 16.7 ms, with 2.02 ms increments) of a
single mid-ventricular short axis slice. Long axis cines
and a contiguous stack of short axis cines were also
acquired to assess left ventricular dimensions and func-
tion [27]. For T2* acquisition a large region of interven-
tricular septum in a mid-ventricular slice was used.
Following T2* acquisition, intravenous gadolinium-
DTPA (0.2 mmol/kg) was administered and LGE images
were obtained in multiple planes after 10 minutes [28].
Multiple acquisitions using an inversion recovery-
prepped gradient echo sequence were obtained with
incrementally increased inversion times (TI) until opti-
mal contrast between normal and abnormal myocar-
dium was obtained with TI = 250 ms. Data analysis was
performed using CMRtools and its plug-in Thalassaemia
Tools (Cardiovascular Imaging Solutions, London UK).
All scans were reported in consensus by two indepen-
dent experienced CMR readers.
Statistics
T2* values do not conform to a Gaussian distribution
and are therefore presented as medians (Q1, Q3) unless
otherwise stated. Comparison of T2* readings were
made using the Mann-Whitney U test and comparisons
of left ventricular indices were performed using
Student’s t test. All normal variables are presented as
mean ± SD and ranges or n (%) as appropriate. Statisti-
cal significance was set at P < 0.05.
Results
Overall patient cohort details
The baseline characteristics of the whole study group
are shown in table 1. There were 42 subjects with nor-
mal left ventricular (LV) ejection fraction (EF > 56%)
and 3 patients with current LV impairment with LVEF
< 56% who were receiving cardiac treatment for heart
failure. Five patients (11%) had a previous history of
heart failure and 4 patients (9%) had history of docu-
mented arrhythmias, all of whom currently has normal
LV function and no heart failure. The median (Q1, Q3)
Table 1 Demographics (mean ± SD unless otherwise
stated)
Total number of patients 45









Units of blood transfused (units/year) 32.2 ± 17.3
Past history cardiac disease
Heart Failure 5 (11%)
Time between heart failure and scan (years) 3.7 ± 7.6
Arrhythmia 4 (9%)
Time between arrhythmia and scan (years) 4.0 ± 6.7
CMR measures:
Cardiac T2* (ms) median (Q1, Q3) 22.6 (13.4, 34.5)
Liver T2* (ms) median (Q1, Q3) 4.4 (2.3, 8.5)
LV end diastolic volume (mL) 134 ± 41.4
LV end systolic volume (mL) 46.4 ± 20.2
LV ejection fraction (%) 65.8 ± 8.5
Chelation
Deferoxamine only 21 (47%)
Deferiprone only 3 (7%)
Deferasirox only 9 (20%)
Deferoxamine & deferiprone 11 (24%)
No Chelation 1 (2%)
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of myocardial T2* in all patients was 22.6 ms (range 5.3-
58.8 ms). Of these patients, 27 had no significant iron
loading (T2* > 20 ms), 15 patients had mild/moderate
iron loading (T2* 10-20 ms) and 3 patients had severe
iron loading (T2* < 10). At the time of the CMR scan, 1
patient was receiving no chelation (post bone marrow
transplant), 21 patients were receiving deferoxamine, 3
patients deferiprone, 11 patients deferoxamine combined
with deferiprone and 9 patients deferasirox only.
No myocardial iron loading group (T2* > 20 ms)
In these 27 patients, the myocardial T2* was 32.0 ms
(26.5, 39.3), liver T2* was 6.8 ms (4.4, 21.0) and the LV
EF was 68.3 ± 8.3%. No patient had a prior history of
heart failure. There was fibrosis in one patient, (T2*
20.1 ms, and LVEF 57%) and there was no past history
of heart failure or arrhythmia. The fibrosis was a small,
discrete area in the subendocardium of the mid-infero-
lateral wall of the LV, with normal myocardial thickness
throughout and no associated regional wall motion
abnormalities (figure 1).
Mild/moderate myocardial iron loading group
(T2* 10-20 ms)
In these 15 patients, the myocardial T2* was 13.1 ms
(11.1, 15.4), liver T2* was 2.9 ms (2.1, 4.3) and the LV EF
was 64.1 ± 6.2%. No patient had cardiac fibrosis despite 2
patients (4%) having a previous episode of heart failure.
When compared with the normal group (T2* > 20), there
was no significant difference in LVEF (p = 0.34).
Severe myocardial iron loading group (T2* < 10)
In these 3 patients, the myocardial T2* was 7.7 ms, liver
T2* 2.2 ms and LV ejection fraction was 54.7 ± 3.5%.
All 3 patients (100%) had a previous history of heart
failure, but no patient has cardiac fibrosis. When com-
pared with the normal group (T2* > 20) the LVEF was
significant reduced (p < 0.01).
Discussion
Macroscopic cardiac fibrosis is detectable using LGE
CMR and occurs commonly in non-ischemic heart dis-
ease such as dilated cardiomyopathy (DCM) [11,15], and
hypertrophic cardiomyopathy (HCM) [12,17]. In DCM
and HCM, the fibrosis is a driver of the development of
LV dysfunction, and is directly linked to adverse cardiac
outcomes such as heart failure and arrhythmias [15,17].
Historical post-mortem studies showed replacement car-
diac fibrosis to be a prominent feature in thalassemia
major patients [4-6], and therefore it is possible that car-
diac fibrosis is important in the development of heart
failure in thalassemia major. However, these studies are
now up to 50 years old, which pre-dates the era of iron
chelation treatment, and were biased towards patients
who had died. More recent histology studies are limited
and mainly in the unrelated genetic condition of heredi-
tary hemochromatosis [7-9]. Our study in the modern
chelation era of living patients, shows a low incidence of
macroscopic myocardial fibrosis of 2% (1 in 45 patients),
and in this one patient the fibrosis was very limited
affecting only 0.4% of total left ventricular mass. This is
Figure 1 Late gadolinium enhancement in the thalassaemia patient. The arrows show a small area of fibrosis in the mid inferolateral wall of
the left ventricle.
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considerably lower than the replacement fibrosis typi-
cally seen in DCM (15%) [15,11] and HCM (30%) [17],
and is unlikely to have any clinical relevance as studies
in myocardial infarction predict a decrement in ejection
fraction of only 0.27% in association with fibrosis of
0.4% of left ventricular mass [29]. If the fibrosis was due
to cardiac siderosis, myocardial iron loading should be
present, but the cardiac T2* was normal at 20.1 ms; or
the patient might have current or a past history of heart
failure, but this was not present and the ejection fraction
was normal at 57%. The 47 year old male patient had
not been investigated by the referring hospital for alter-
native, more prevalent causes of fibrosis, such as coron-
ary disease, but was hepatitis C antibody positive.
Another significant discrepancy related to the possibi-
lity of cardiac fibrosis causing ventricular dysfunction in
thalassemia major is that the dysfunction can be
reversed with successful iron chelation therapy with
intravenous deferoxamine [3], or combination deferoxa-
mine-deferiprone [30]. The left ventricular ejection frac-
tion increases as cardiac T2* improves, however there is
no obvious pathophysiological mechanism for reversible
effects of replacement fibrosis on ejection fraction.
When the association of improved ejection fraction and
improved cardiac T2* is married with the knowledge
that low cardiac T2* is a potent predictor of future car-
diac events [31], it becomes difficult to ascribe a signifi-
cant clinical role to another factor such as putative
reversible fibrosis. The lack of replacement fibrosis in
our patients who had a history of heart failure or cur-
rent left ventricular impairment would add credence to
this position. We posit therefore that the left ventricular
impairment seen in cardiac siderosis is a direct result of
myocardial iron deposition and any contribution from
replacement fibrosis is limited.
There is one previous study using CMR LGE in tha-
lassemia from Pepe et al [10], which found LGE in 28 of
115 patients (24%). There are a number of possible
explanations for the discrepancy of this study with ours.
The LGE techniques or the interpretation of the images
or the population studied may have differed between the
2 studies. The age and mean cardiac T2* of Pepe’s
patients was 27.2 years and 24.5 ms, compared with
27.1 years and a median of 22.6 ms in our study, which
excludes these as possible causal differences. However
there was a high level of hepatitis C antibodies in Pepe’s
patients (71%) which may indicate an additional
mechanism for LGE such as myocarditis, which might
resolve the differences in LGE prevalence between the 2
studies. In our study, only 11/49 (22%) patients were
hepatitis C antibody positive, which included our one
patient with LGE. We also note that the quantification
of mean LGE extent by Pepe et al was 3.9% which
indicates that the patches of fibrosis in their study were
very limited and unlikely to be clinically significant with
regard to cardiac dysfunction.
Limitations
LGE shows in-vivo macroscopic fibrosis, but interstitial
fibrosis is too fine to be detected. However new techniques
with T1 mapping [32], or steady state gadolinium infu-
sions [33], to detect microscopic (non-replacement) fibro-
sis may prove useful. We have no tissue analysis from our
study examining molecular markers of cardiac fibrogen-
esis. mRNA studies in ex-vivo cardiac myocytes have
shown iron level dependent reductions in expression of
transforming growth factor-b1 (TGF-B1), biglycan, and
collagen type I, which was accompanied by a reduction in
TGF-B1 bioactivity, which does not obviously support
iron-driven cardiac fibrogenesis [34]. However, other stu-
dies suggest that myocytes can suppress proliferation of
fibroblasts by cumulative effects on late G1 events leading
to DNA synthesis, and these effects are diminished with
myocyte iron accumulation [35,36]. A contemporary his-
tology study in thalassemia major examining myocardium
directly for interstitial fibrosis would be useful to add
further evidence to the debate.
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